Overview
Savio Gontijo practices practicing medicine in Belo Horizonte, Brazil.
Their clinical expertise encompasses Squamous Cell Skin Carcinoma, Delayed Growth, and Triple-Negative Breast Cancer.
They are actively involved in clinical research, co-authoring 11 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Savio L. Gontijo
Is Savio L. Gontijo a top-rated expert for Squamous Cell Skin Carcinoma?
MediFind is an objective health platform that identifies experts based on real-world data. Savio L. Gontijo is classified as an Experienced expert for Squamous Cell Skin Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Savio L. Gontijo participate in research or clinical trials?
Yes. Savio L. Gontijo has published 11 articles and abstracts on conditions like Squamous Cell Skin Carcinoma. You can view a list of Savio L. Gontijo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Delayed GrowthGontijo isExperienced. Learn about Delayed Growth.
- Squamous Cell Skin CarcinomaGontijo isExperienced. Learn about Squamous Cell Skin Carcinoma.
- Triple-Negative Breast CancerGontijo isExperienced. Learn about Triple-Negative Breast Cancer.